

**Wetenschappelijke Publicaties**

1. Van Oostrom CThM, De Vries A, Verbeek SJ, Van Kreijl CF, Van Steeg H. Cloning and characterization of the mouse *XPAC* gene. **Nucleic Acids Research**;22:11-14 (1994)
2. De Vries A, Van Oostrom CThM, Hofhuis FMA, Dortant PM, Berg RJW, De Gruijl FR, Wester PW, Van Kreijl CF, Capel PJA, Van Steeg H, Verbeek SJ. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene *XPA*. **Nature**;377:169-173 (1995)
3. De Vries A, Van Steeg H. *XPA* knockout mice. **Seminars in Cancer Biology**;7:229-240 (1996)
4. De Vries A, Van Oostrom CThM, Dortant PM, Beems RB, Van Kreijl CF, Capel PJA, Van Steeg H. Spontaneous liver tumors and benzo[a]pyrene-induced lymphomas in *XPA*-deficient mice. **Molecular Carcinogenesis**;19:46-53 (1997)
5. Berg RJW, De Vries A, Van Steeg H, De Gruijl FR. Relative susceptibilities of *XPA* knockout mice and their heterozygous and wild-type littermates to UVB-induced skin cancer. **Cancer Research**; 57: 581-584 (1997)
6. De Vries A, Dollé MET, Broekhof JLM, Muller AJJA, Kroese ED, Van Kreijl CF, Capel PJA, Vijg J, Van Steeg H. Induction of DNA adducts and mutations in spleen, liver and lung of *XPA*-deficient/*lacZ* transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumour development. **Carcinogenesis**;8:2327-2332 (1997)
7. De Vries A, Berg RJW, Wijnhoven S, Westerman A, Wester PW, Van Kreijl CF, Capel PJA, De Gruijl FR, Van Kranen HJ, Van Steeg H. *XPA*-deficiency in hairless mice causes a shift in skin tumor types and mutational target genes after exposure to low doses of UVB. **Oncogene**;16:2205-2212 (1998)
8. Frijhoff AFW, Krul CAM, Kelders MCJM, De Vries A, Weeda G, Van Steeg H, Baan RA. Influence of nucleotide excision repair on N-hydroxy-2-acetylaminofluorene induced mutagenesis studied in lambda *lacZ* transgenic mice. **Environmental Molecular Mutagenesis**;31:41-47 (1998)
9. Bol SAM, Van Steeg H, Jansen JG, Van Oostrom C, De Vries A, De Groot AJL, Tates AD, Vrieling H, Van Zeeland AA, Mullenders LHF. Elevated frequencies of Benzo[a]pyrene-induced HPRT mutations in internal tissue of *XPA*-deficient mice. **Cancer Research**;58:2850-2857 (1998)
10. De Vries A, Gorgels TGMF, Berg RJW, Jansen GH, Van Steeg H. Ultraviolet-B induced hyperplasia and squamous cell carcinomas in the cornea of *XPA*-deficient mice. **Experimental Eye Research**;67:53-59 (1998)
11. Van Oostrom CT, Boeve M, van den Berg J, De Vries A, Dolle ME, Beems RB, van Kreijl CF, Vijg J, Van Steeg H. Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient *XPA* mice. **Environmental Molecular Mutagenesis**;34:124-130 (1999)
12. Van Steeg H, De Vries A, van Oostrom CTh, van Benthem J, Beems RB, Van Kreijl CF. DNA repair-deficient *Xpa* and *Xpa/p53+/-* knock-out mice: nature of the models. **Toxicology Pathology**;29:Suppl:109-116 (2001)
13. De Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. **The Proceedings of the National Academy of Sciences**; 99(5):2948-2953 (2002)
14. Hoogervorst EM, De Vries A, Beems RB, Van Oostrom CTM, Wester PW, Vos JG, Bruins W, Roodbergen M, Cassee FR, Vijg J, van Schooten FJ, Van Steeg H. Combined oral benzo[a]pyrene and inhalatory ozone exposure have no effect on lung tumor development in DNA repair-deficient *Xpa* mice. **Carcinogenesis**; 24 (3):613-619 (2003)
15. Attardi LD, De Vries A, Jacks T. Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer. **Oncogene** 23, 973-980 (2004)

16. Iwakuma T, Parant JM, Fasulo Jr. M, Zwart E, Jacks T, De Vries A, Lozano G. Mutation at p53 serine 389 does not rescue the embryonic lethality in *mdm2* or *mdm4* null mice. **Oncogene** 23, 7644-7650 (2004)
17. MacPherson D, Kim, J, Kim T, Rhee BK, Van Oostrom CTM, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser23. **EMBO Journal**, 23 (18): 3689-3699 (2004)
18. Hoogervorst EM, Van Oostrom CTM, Beems RB, Van Benthem J, Gielis SF, Vermeulen JP, Wester PW, Vos JG, De Vries A, Van Steeg H. p53 heterozygosity results in an increased 2-AAF-induced urinary bladder, but not liver tumor response in DNA repair deficient *Xpa* mice. **Cancer Research**, 1;64(15):5118-26 (2004)
19. Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, Van Oostrom CTM, Van den Berg J, Van den Aardweg GJ, Lozano G, Van Steeg H, Jacks T, De Vries A. Increased sensitivity to UV radiation in mice with a p53 point mutation at Ser389. **Molecular and Cellular Biology**, 24 (20) 8884-8894 (2004)
20. Hoogervorst EM, Van Oostrom CTM, Beems RB, Van Benthem J, Van den Berg J, Van Kreijl CF, Vos JG, De Vries A, Van Steeg H. 2-AAF-induced tumor development in nucleotide excision repair-deficient mice is associated with a defect in global genome repair but not with transcription coupled repair. **DNA Repair**, 4(1):3-9 (2005)
21. Hoogervorst EM, Van Steeg H, De Vries A. Nucleotide Excision Repair- and p53-deficient mouse models in cancer research. **Mutation research**, 574(1-2):3-21 (2005)
22. Hoogervorst EM, Bruins W, Zwart E, Van Oostrom CTM, Van den Aardweg GJ, Beems RB, Van den Berg J, Jacks T, Van Steeg H, De Vries A. Lack of p53 Ser389 phosphorylation predisposes mice to develop 2-acetylaminofluorene-induced bladder tumors but not ionizing radiation-induced lymphomas. **Cancer Research**, 65(9):3610-6 (2005)
23. Wijnhoven SWP, Zwart E, Speksnijder EN, Beems RB, Olive KP, Tuveson DA, Jonkers J, Schaap MM, Van den Berg J, Jacks T, Van Steeg H, De Vries A. Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. **Cancer Research**, 65(18):8166-73 (2005)
24. Wijnhoven SWP, De Vries A. 'Tumor Suppressor Genes' In: *Encyclopedic Reference of Genomics and Proteomics in Molecular Medicine*. Ganten, D., Ruckpaul, K. (Eds). LXIV, 2112 P., ISBN: 3-540-44244-8 (2006)
25. Baken KA, Pennings JLA, Breit TM, De Vries A, Van Steeg H, Van Loveren H. Gene expression profiling of bis(tri-n-butyltin)oxide (TBTO) induced immunotoxicity in mice and rats. **Journal of Immunotoxicology**, 3:227-244 (2006)
26. Kooter IM, Pennings JL, Fokkens PH, Leseman DL, Boere AJ, Gerlofs-Nijland ME, Cassee FR, Schalk JA, Orzechowski TJ, Schaap MM, Breit TM, Dormans JA, Van Oostrom CT, De Vries A, Van Steeg H. Ozone induces clear cellular and molecular responses in the mouse lung independently of the transcription-coupled repair status. **Journal of Applied Physiology**, 102(3): 1185-92 (2007)
27. Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, Van Oostrom CT, Beems RB, Hoogervorst EM, Schaap MM, Attardi LD, Jacks T, Van Steeg H, Jonkers J, De Vries A. Dominant-negative but not gain of function effects a p53.R270H mutation in mouse epithelium tissue after DNA damage. **Cancer Research**, 67(10):4648-56 (2007)
28. Bruins W, Jonker MJ, Bruning O, Pennings JL, Schaap MM, Hoogervorst EM, Van Steeg H, Breit TM, De Vries A. Delayed Expression of Apoptotic and Cell Cycle Control Genes in Carcinogen-Exposed Bladders of Mice Lacking p53.S389 Phosphorylation. **Carcinogenesis**, 28(8):1814-23 (2007)
29. Knoops L, Haas R, de Kemp S, Majoor D, Broeks A, Eldering E, de Boer JP, Verheij M, van Oostrom C, De Vries A, Van 't Veer L, De Jong D. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. **Blood**, 110(4):1116-22 (2007)

30. Bruins W, Bruning O, Jonker MJ, Zwart E, van der Hoeven TV, Pennings JL, Rauwerda H, De Vries A, Breit TM. The absence of Ser389 phosphorylation in p53 affects the basal gene-expression level of many p53-dependent genes and alters the biphasic response to UV exposure in mouse embryonic fibroblasts. **Molecular and Cellular Biology**, 28(6):1974-87 (2008)
31. Mahabir AG, van Benthem J, Korsten H, Lynch AM, Bailey L, De Vries A, Hendriksen CF, Van Steeg H. Detecting genotoxic effects of potential clastogens: An *in vivo* study using the transgenic lacZ plasmid and the Mutatrade markMouse model. **Mutation Research**, 652(2):151-157 (2008)
32. Baken KA, Pennings JLA, Jonker MJ, Schaap MM, De Vries A, Van Steeg H, Breit TM, Van Loveren H. Overlapping gene expression profiles of model compounds provide opportunities for immunotoxicity screening. **Toxicology and Applied Pharmacology**, 226(1):46-59 (2008)
33. Mahabir AG, Schaap M, Theunissen P, van Benthem J, Essers J, De Vries A, Hendriksen CF, Van Steeg H. DNA-repair-deficient Rad54/Rad54B mice are more sensitive to clastogens than wild-type mice. **Toxicology Letters**, 183(1-3):112-7 (2008)
34. Van Kesteren PC, Beems RB, Luijten M, Robinson J, De Vries A, Van Steeg H. DNA repair-deficient Xpa/p53 knockout mice are sensitive to the non-genotoxic carcinogen cyclosporine A: escape of initiated cells from immunosurveillance? **Carcinogenesis**, 30(3):538-43 (2009)
35. Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, De Vries A, Jonkers J. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. **Cancer Research**, 69(8):3625-33 (2009)
36. Mahabir AG, Zwart E, Schaap M, van Benthem J, De Vries A, Hernandez LG, Hendriksen CF, Van Steeg H. LacZ mouse embryonic fibroblasts detect both clastogens and mutagens. **Mutation Research**, 666(1-2):50-56 (2009)
37. Koster MPH, Pennings JLA, Imholz S, Rodenburg W, Visser GHA, De Vries A, Schielen PCJI. Bead-based multiplexed immunoassays to identify new biomarkers in maternal serum to improve first trimester Down syndrome screening. **Prenatal Diagnosis**, 29(9):857-62 (2009)
38. Jonker MJ, Bruning O, Van Iterson M, Schaap MM, Van der Hoeven T, Vrieling H, Beems DB, De Vries A, Van Steeg H, Breit TM, Luijten M. Finding transcriptomics biomarkers for *in vivo* identification of (non-)genotoxic carcinogens using wild-type and Xpa/p53 mutant mouse models. **Carcinogenesis**, 30(10):1805-1812 (2009)
39. Pennings JL, Koster MP, Rodenburg W, Schielen PC, De Vries A. Discovery of novel serum biomarkers for prenatal Down syndrome screening by integrative data mining. **PLoS One**. 24;4(11):e8010 (2009)
40. Rodenburg W, Pennings J, Van Oostrom C, Roodbergen M, Luijten M, De Vries A. Identification of breast-cancer biomarkers in transgenic mouse models: a Proteomics approach. **Proteomics Clinical applications**, 4(6-7):603-12 (2010)
41. Bruning O, Yuan X, Rodenburg W, Bruins W, van Oostrom CT, Rauwerda H, Wittink FR, Jonker MJ, De Vries A, Breit TM. Serious complications in gene-expression studies with stress perturbation: An example of UV-exposed p53-mutant mouse embryonic fibroblasts. **Transcription**, 1(3):159-164 (2010)
42. Koster MP, Pennings JL, Imholz S, Rodenburg W, Visser GH, De Vries A, Schielen PC. Proteomics and Down syndrome screening: a validation study. **Prenat Diagn**. 30(11):1039-43 (2010)
43. Koster MP, Heetkamp KM, Pennings JL, De Vries A, Visser GH, Schielen PC. Down syndrome screening: imagining the screening test of the future. **Expert Rev Mol Diagn**. 10(4):445-57 (2010)
44. Zhu F, Dollé ME, Berton TR, Kuiper RV, Capps C, Espejo A, McArthur MJ, Bedford MT, van Steeg H, De Vries A, Johnson DG. Mouse models for the p53 R72P polymorphism mimic human phenotypes. **Cancer Res**. 70(14):5851-9 (2010)

45. Pennings JL, Rodenburg W, Imholz S, Koster MP, van Oostrom CT, Breit TM, Schielen PC, De Vries A. Gene expression profiling in a mouse model identifies fetal liver- and placenta-derived potential biomarkers for down syndrome screening. **PLoS One**. 6(4):e18866 (2011).
46. Melis JP, Hoogervorst EM, van Oostrom CT, Zwart E, Breit TM, Pennings JL, De Vries A, van Steeg H. Genotoxic exposure: novel cause of selection for a functional  $\Delta N$ -p53 isoform. **Oncogene**. 30(15):1764-72 (2011)
47. Koster W, De Vries A, Visser G, Schielen P. Innovations in Down syndrome screening. In: *Prenatal Diagnosis and Screening for Down Syndrome*. InTech, Chapter 8:131-148 (2011)
48. Pennings JL, Kuc S, Rodenburg W, Koster MP, Schielen PC, De Vries A. Integrative data mining to identify novel candidate serum biomarkers for pre-eclampsia screening. **Prenat Diagn**. 31(12):1153-9 (2011)
49. Pennings JL, De Vries A. Toxicoproteomics. **TCDD** (4):8-9 (2011)
50. Rodenburg W, Reimerink JH, Imholz S, Godeke GJ, Pennings JL, Schielen PC, Koster MP, De Vries A. Quantitative performance of antibody array technology in a prenatal screening setting. **Clin Chem Lab Med**. Epub Oct 28 (2011)
51. Bruning O, Rodenburg W, Radonic T, Zwinderman AH, De Vries A, Breit TM, de Jong M. RNA isolation for transcriptomics of human and mouse small skin biopsies. **BMC Res Notes**. 24;4:438 (2011)
52. Pennings JLA, Van Dycke KCG, van Oostrom CTM, Kuiper RV, Rodenburg W, De Vries A. Biomarker discovery using a comparative omics approach in a mouse model developing heterogeneous mammary cancer subtypes. **Proteomics**, 12(13):2149-57 (2012)
53. Opstal-van Winden AWJ, Rodenburg W, Pennings JLA, van Oostrom CTM, Beijnen JH, Peeters PHM, van Gils CH, de Vries A. A Bead-based Multiplexed Immunoassay to Evaluate Breast Cancer Biomarkers for Early Detection in Pre-Diagnostic Serum. **Int. J. Mol. Sci.**, 13(10), 13587-13604 (2012)

#### RIVM rapporten/brief rapporten

1. De Vries A, Van Oostrom CThM, Dortant PM, Wester PW, Van Kreijl CF and Van Steeg H. Identifying carcinogens in short-term bioassays using DNA repair deficient transgenic mice. In: RIVM, Annual Scientific Report 1995. Bilthoven, pp. 28 – 31. (1996)
2. De Vries A, Van Steeg H & Opperhuizen A. Transgenic mice as alternatives for carcinogenicity testing: current status. (2003)
3. De Vries A. Toxicogenomics in risicoschatting: Valide alternatief? (2004)
4. De Vries A. Toxicogenomics in verplichtte genotoxiciteits testen: effectieve bijdrage 3 V's? (2004)
5. De Vries A, Van Steeg H. Terugdringen proefdiergebruik in verplichte carcinogeniteitstesten m.b.v. het inzetten van transgene muismodellen. (2005)
6. De Vries A, Van Steeg H. Mogelijkheden gebruik van (toxico)genomics ter verbetering risico evaluatie van kankerverwekkende stoffen (2005)
7. Luijten M, De Vries A, Opperhuizen A, Piersma AH. Alternative methods in reproductive toxicity testing: state of the art (2007)
8. De Vries A. Biomarkers van kanker: een eerste introductie (2007)
9. Rodenburg W, De Vries A. Biomarkers in Breast Cancer screening: a future approach? (2008)
10. Boer J, Van Bakel M, Hoogervorst E, Luijten M, De Vries A. Effects of maternal diet during pregnancy on birth weight of the infant (2009)
11. Rodenburg W, Koster W, Pennings J, Heijnen M-L, De Vries A. Signalement: Innovaties in de prenatale screening op downsyndroom (2012)

12. Rodenburg W, Spijkerman A, Imholz S, Pennings J, de Vries A. Biomarkers en predictiemodellen voor vroege detectie van borstkanker in de algemene populatie. (2012)